Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

This study will evaluate the antiviral efficacy, safety, and tolerability of combination therapy with oral regimens for the treatment of chronic hepatitis C virus (HCV) infection.

Key Inclusion Criteria:

• Willing and able to provide written informed consent
• Chronic HCV infection
• Cirrhosis determination (liver biopsy may be required)
• Screening laboratory values within specified limits
• Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
• Specific genotype, prior medical history, or concurrent disease as required by the specific study group

Key Exclusion Criteria:

• History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
• Pregnant or nursing female, or male with pregnant female partner
• Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)
• Use of any prohibited concomitant medications

Note: Other protocol defined Inclusion/Exclusion criteria may apply.